Paul Conyngham’s cancer vaccine is an example of AI behaving as a normal technology

Paul Conyngham, an Australian entrepreneur, used AI tools including ChatGPT to help design a personalized mRNA vaccine that successfully treated his dog's mast cell cancer, a story that has sparked both skepticism and hype online. The vaccine was developed in collaboration with researchers at the University of New South Wales (UNSW), who handled critical steps like genome sequencing and vaccine synthesis. AI assisted in identifying neoantigens—mutant proteins unique to the dog's tumor—and optimizing the vaccine's design, but the process still relied heavily on human expertise and established scientific protocols. This case underscores AI's role as a normal technology that augments, rather than replaces, scientific work.

Personalized mRNA vaccines represent a promising frontier in cancer treatment, as they can target individual tumors' unique genetic profiles. Unlike off-the-shelf vaccines, which use fixed antigen sets and often fall short for specific patients, personalized versions like this one sequence the patient's genome to design custom vaccines. Clinical trials, such as Moderna and Merck's Phase IIb mRNA-4157 trial, have shown a 49% reduction in recurrence risk for melanoma patients. Conyngham's story, while anecdotal, demonstrates how AI can accelerate such efforts by analyzing genetic data and suggesting optimal targets, though human oversight remains essential for safety and efficacy.